ProfileGDS5678 / 1431513_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 43% 42% 42% 41% 43% 44% 43% 42% 41% 50% 42% 42% 42% 42% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0241343
GSM967853U87-EV human glioblastoma xenograft - Control 22.9718542
GSM967854U87-EV human glioblastoma xenograft - Control 32.9789142
GSM967855U87-EV human glioblastoma xenograft - Control 42.8809641
GSM967856U87-EV human glioblastoma xenograft - Control 52.9515743
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.1033144
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0517943
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9557142
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9179941
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.1719950
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9701142
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9327942
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9758142
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9555342